Pfarr, Egon

SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: A meta-analysis of the EMPEROR-Reduced and DAPA-HF trials

Zannad, F., Ferreira, J. P., Pocock, S. J., Anker, S. D., Butler, J., Filippatos, G., Brueckmann, M., Ofstad, A. P., Pfarr, E., Jamal, W., et al. (2020) · The Lancet

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 1,408

Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin

Cherney, D. Z. I., Cooper, M. E., Tikkanen, I., Pfarr, E., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Lund, S. S. (2018) · Kidney International

Diabetes Treatment and ManagementBlood Pressure and Hypertension Studies

Cited by 243

Empagliflozin and Assessment of Lower-Limb Amputations in the EMPA-REG OUTCOME Trial

Inzucchi, S. E., Iliev, H., Pfarr, E., & Zinman, B. (2018) · Diabetes Care

Diabetes Treatment and ManagementDiabetic Foot Ulcer Assessment and Management

Cited by 162

Cost-effectiveness of empagliflozin in patients with diabetic kidney disease in the United States: findings based on the EMPA-REG OUTCOME trial

Reifsnider, O. S., Kansal, A. R., Wanner, C., Pfarr, E., Koitka-Weber, A., Brand, S. B., Stargardter, M., Wang, C., Kuti, E., & Ustyugova, A. (2022) · American Journal of Kidney Diseases

Health Systems, Economic Evaluations, Quality of LifeDiabetes Treatment and Management

Cited by 52

Cost‐effectiveness analysis of empagliflozin treatment in people with Type 2 diabetes and established cardiovascular disease in the EMPA‐REG OUTCOME trial

Kansal, A., Reifsnider, O. S., Proskorovsky, I., Zheng, Y., Pfarr, E., George, J. T., Kandaswamy, P., & Ruffolo, A. (2019) · Diabetic Medicine

Health Systems, Economic Evaluations, Quality of LifeDiabetes Treatment and Management

Cited by 42